SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood–brain barriers

Author: Shubar Hend M.   Lachenmaier Sabrina   Heimesaat Markus M.   Lohman Uwe   Mauludin Rachmat   Mueller Rainer H.   Fitzner Rudolf   Borner Klaus   Liesenfeld Oliver  

Publisher: Informa Healthcare

ISSN: 1061-186X

Source: Journal of Drug Targeting, Vol.19, Iss.2, 2011-02, pp. : 114-124

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content